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Abstract Heart failure (HF) is one of the major health
and economic burdens worldwide, and its prevalence is
continuously increasing. The study of HF requires reliable
animal models to study the chronic changes and pharma-
cologic interventions in myocardial structure and function
and to follow its progression toward HF. Indeed, during the
past 40 years, basic and translational scientists have used
small animal models to understand the pathophysiology of
HF and find more efficient ways of preventing and man-
aging patients suffering from congestive HF (CHF). Each
species and each animal model has advantages and disad-
vantages, and the choice of one model over another should
take them into account for a good experimental design. The
aim of this review is to describe and highlight the advan-
tages and drawbacks of some commonly used HF rodents
models, including both non-genetically and genetically
engineered models, with a specific subchapter concerning
diastolic HF models.
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Introduction
Heart failure (HF) is a complex syndrome in which patients
should present the following characteristics: symptoms of
HF, signs of fluid retention and objective evidence of an
abnormality of the cardiac structure or function at rest [53].
It is often divided in two distinct entities, namely systolic
heart failure (SHF) and diastolic heart failure (DHF) or, in
alternative, HF with reduced ejection fraction and HF with
preserved ejection fraction, respectively. Despite the hot
controversy on the definition of each entity, SHF is char-
acterized by an inability of the myocardium to contract and
eject blood, while DHF refers to a disturbance in accom-
modating blood volume during diastole at low filling
pressures, due to impaired ventricular relaxation (primarily
affecting early diastole) or increased myocardial stiffness
(primarily affecting late diastole) [152]. Besides defective
myocardial relaxation, the mechanisms underlying DHF
include abnormal extracellular matrix dynamics and altered
myocyte cytoskeleton, which could interfere with the
passive properties of the ventricular wall [152].
The great majority of animal models have been devel-
oped for SHF. Besides being rather difficult to replicate
pure DHF in animal models, these are also more
demanding and time-consuming than SHF. Therefore, not
surprisingly most HF models developed so far represent
SHF.
Non-genetically engineered rodent models
Pharmacologically induced cardiomyopathy
Doxorubicin
Doxorubicin (adriamycin, DOX) is an anthracycline widely
used in cytostatic treatments. One of the major long-term
consequences of DOX therapy is the development of car-
diomyopathy and ultimately CHF in humans as in experi-
mental animals. Therefore, understanding the pathogenesis
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of cardiotoxic cardiomyopathy is essential to the develop-
ment of new measures to prevent cardiotoxicity associated
with antineoplastic therapies. DOX causes a dose-depen-
dent cardiotoxicity and thus has been used to induce HF in
various animal species [21, 37, 291, 293].
DOX administration once a week for 6 weeks or on
alternate days for 2 weeks has been shown to induce car-
diomyopathy and HF [51, 168, 284]. Interestingly, a single
dose of DOX has been shown to induce significant left
ventricular (LV) dysfunction in mice after 5 days [189].
This drug is usually administered by intravenous or intra-
coronary injection. The latter allows delivery of DOX at a
smaller dose to induce HF without systemic toxicity [203].
DOX-induced cardiomyopathy is characterized by ven-
tricular wall thinning and dilatation, and depressed systolic
and diastolic function [22, 50, 168, 291] accompanied by
fluid retention and by neurohumoral activation [8]. At the
cardiac muscle level, DOX promotes intrinsic contractile
dysfunction and reduced contractile reserve [21, 22, 50].
Furthermore, DOX impairs vascular [208] as well as
endocardial [21] endothelial function and [27, 151, 287]
induces inflammatory reactions in the heart, leading to
thrombosis in the atria and myocarditis [27, 75, 78, 293].
Multiple pathways of anthracycline-induced cardiac
cellular injury have been proposed such as the release of
cardiotoxic substances, which subsequently accumulate in
cardiomyocytes [185], the generation of free radical, lipid
peroxidation, and suppression of DNA, RNA and protein
synthesis [255, 276]. Other studies suggest that cardio-
toxicity pathways include abnormalities in Ca2? handling
[50, 54, 285]; induction of mitochondrial DNA lesions
[149]; degradation of myofilamental and cytoskeletal pro-
teins, including titin [160] and dystrophin [40]; interference
with various pro-survival kinases [224]; and changes in
adrenergic and adenylate cyclase function [33, 74]. These
examples of a much larger set of proposed cardiotoxic
mechanisms are not mutually exclusive: they may each
contribute to cardiac cell damage, ultimately leading to
myocyte death, by either necrosis or apoptosis [254].
Additionally, it was recently demonstrated that DOX car-
diomyopathy can be also mediated by depletion of the
cardiac stem cell pool and rescued by restoration of pro-
genitor cell function [50].
Spontaneous hypertensive rats (SHR) are more sensitive
to the toxic effects of DOX [98], probably because of the
low free radical–scavenging ability of their myocardium
[122].
DOX model has a short time course of induction of HF
and also the advantages of being technically simple,
reproducible, non-invasive and economical. Additionally,
it can be used in several animal species to promote either
chronic or acute HF [203]. The main limitations of this
model are related to the variable degree of ventricular
dysfunction and the high incidence of arrhythmias that
contribute to the high mortality rate. Anthracycline
administration also has undesirable bone marrow, gastro-
intestinal and renal toxicities that can however be elimi-
nated by the intracoronary injection of the drug [8, 203].
Homocysteine
Hyperhomocysteinemia has been identified as a causative
factor of cardiac stress and dysfunction in both spontaneous
hypertensive and normotensive rats [129, 130]. In rats,
supplementation of diet with homocysteine for 10 weeks
produces hyperhomocysteinemia and consequently ven-
tricular dysfunction with compromised systolic and dia-
stolic function [52, 130]. The main factors involved in the
development of HF are oxidative stress and inflammatory
mediators [129].
Isoproterenol
Excessive doses of catecholamines produce diffuse myo-
cardial destruction with cardiomyocyte necrosis and
extensive fibrosis in both animals and humans [219, 220,
292]. The mechanism underlying myocardial damage is
likely related to an imbalance between oxygen supply
versus demand due to myocardial hyperactivity [62]. In
mice, infusion of isoproterenol for 7 days has been shown
to induce cardiac dysfunction [216]. In rats, subcutaneous
administration of isoproterenol for 3 days leads to a dose-
dependent impairment of cardiac function and neurohu-
moral activation [88, 325], with cardiomyocyte necrosis
and extensive LV hypertrophy and dilation and after 2 and
12 weeks, respectively [92, 324]. However, isoproterenol
administration before ischemia exerts a cardioprotective
effect in rats [92]. The advantages of this model are its
technical simplicity and excellent reproducibility in asso-
ciation with a satisfactory low mortality. Nonetheless, it
seems not suitable for inducing an overt state of CHF
because higher doses of catecholamines can increase the
mortality rate up to 80% [88].
Monocrotaline
Monocrotaline (MCT) is a plant toxin derived from
Crotalaria spectabilis that can be administered by intra-
peritoneal, subcutaneous or intravenous injection to induce
right ventricular dysfunction and HF within 4–6 weeks [30,
299]. Current hypotheses of the pathogenesis of MCT-
induced pneumotoxicity suggest that MCT is transformed
in a bioactive pyrrole metabolite in the liver and is then
transported by red blood cells to the lung, where it initiates
endothelial injury. The metabolite has a half-life of *3 s
in aqueous media and primarily affects the pulmonary
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vascular bed as lungs are the first major vascular bed after
the liver [230]. Nonetheless, MCT can injury other struc-
tures such as liver [135] or kidney [262]. In the pulmonary
vasculature, MCT induces perivascular inflammation,
platelet activation and endothelial dysfunction, generally
leading to increased pulmonary arterial pressure. These
changes are accompanied by increase in RV systolic and
diastolic pressures, hypertrophy and ultimately HF [99,
310]. Besides inducing HF, MCT is a simple model which,
at an earlier phase, shares some similarities with human
pulmonary hypertension.
Myocardial infarction-induced HF
Since ischemic heart disease is the most important cause of
human HF, coronary artery occlusion is the most common
method of inducing acute myocardial damage in animal
models. Ligation of the left anterior descending (LAD)
coronary artery or one of its branches remains the most
preferred and acceptable method of inducing regional
injury and subsequent HF in rodents [10, 85], as well as to
gain further insight into pathophysiology of post-myocar-
dial infarction (MI) cardiac remodeling [12, 223]. The
mechanisms responsible for cardiac remodeling are mostly
related to changes in extracellular matrix of the remaining
overloaded myocardium and neurohumoral activation
[72, 156, 234].
Surviving mice gradually develop HF within the
4 weeks following the surgical procedure [76, 155, 158]. In
rats, a significant decrease up to 25% in cardiac output is
observed 8 weeks after LAD ligation [115]. The infarct
size varies significantly (between 10 and 45%) and is
directly related to the degree of LV function impairment
[228], influencing the time course of CHF development
[10]. Generally, the infarct extension needs to affect at least
30% of the LV mass in order to present the typical char-
acteristics of CHF and to induce considerable increases in
the molecular markers of hypertrophy [10]. Age also exerts
a noteworthy effect on the time course of CHF develop-
ment, with young animals tolerating well LAD ligation
without CHF signs, in spite of the larger infarct size [85].
Some recent studies showed that female mice undergo less
extensive ventricular remodeling, suggesting the influence
of sex hormones as a putative explanation for gender dif-
ferences [315].
In both mice and rats, mortality ranges between 35 and
50% and occurs within the first hour after MI due to ven-
tricular fibrillation and severe acute HF [79, 144]. Fur-
thermore, in rats, it seems to be strain dependent with
Lewis inbred rats surviving more than Sprague–Dawley
rats [164].
Contrary to the clinical situation, in which the patient
has progressive non-occlusive coronary artery obstruction,
myocardial infarct in this model is due to the sudden
occlusion of a normal coronary artery. Therefore, efforts
have been made to create a model of chronic myocardial
ischemia, more similar to the clinical reality. Indeed, a
mice model of hyperlipidemia and atherosclerosis with
multiple infarction and CHF has been described. However,
those high-density lipoprotein receptor SR-B1 and apoli-
poprotein-E double knockout mice survive only few weeks
after birth limiting their use in HF research [23].
Protocols of temporary LAD occlusion have been
developed to reproduce human ischemia–reperfusion
injury. This model has confirmed the benefits of reperfu-
sion since infarct size was found to be significantly lower
than after permanent occlusion of the coronary artery.
However, they also revealed the diversity of results as a
consequence of mouse left coronary anatomic high vari-
ability [187].
The procedure was further modified to analyze ischemic
preconditioning of the heart. In this method, LAD is
repeatedly occluded to subject the heart to several rounds
of brief ischemia and reperfusion before permanent
occlusion. Molecular analyses identified various ischemia-
induced genes that confer tolerance to subsequent ischemic
event [311].
The cost and simplicity confer important advantages to
LAD ligation. On the other hand, rat differs from human in
terms of electrophysiology, coronary circulation, cardiac
protein isoforms and time course of MI evolution. In fact,
available data point to a faster onset of healing and ter-
mination processes in rats [142], which mean results must
be interpreted with caution.
An alternative model of MI was cryoinfarction, which
induces a series of cryoinjuries in the epicardium of mice
and rats [245]. However, it has not caught the interest of
the scientific community, and thus, it is no longer used.
Myocarditis-induced HF
Viral myocarditis is a common cause of dilated cardio-
myopathy and HF. The coxsackie-B3 virus (CB3) and the
encephalomyocarditis virus (EMCV) have been used to
induce myocarditis in rodents [102, 213, 318]. EMCV
infection can lead to myocyte necrosis and significant
biventricular dilation during the phase of viremia, while
typical signs of CHF appear after 7–14 days of virus
inoculation [68, 177, 213]. This model is limited to Balb/c
and DBA/2 mice because other mouse strains are resistant
to virus infection [306]. Virus inoculation in genetic
engineered mice has been shedding light on the molecules
involved in the pathogenesis of viral myocarditis. Indeed,
the administration of an exogenous antitumor necrosis
factor-a (anti-TNF-a) antibody reduced myocardial lesion
and improved survival, mitigating the effect of the
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observed increase in TNF-a expression [178]. A retrovirus
model of encephalitis and myocarditis in mice showed that
nuclear factor-kB activation confers protection against
virally mediated apoptosis and its expression is preserved
in the presence of interferon-b. The absence of any of these
molecules in the myocardium leads to striking viral
infection and cell death [214]. Transgenic knockout models
of components of the immune system have provided
interesting insights in the pathogenesis of viral myocarditis
[163].
Another pathogenic agent capable of causing myocarditis
and dilated cardiomyopathy is the protozoan parasite
Trypanosoma cruzi, which causes Chagas disease, a major
form of HF in Latin America [46]. The infection causes
generalized vascular inflammation, which stimulates the
production of endothelin-1 and thromboxane-A2, further
enhancing coronary vasospasm and myocardial ischemia
[35].
Autoimmune myocarditis has been induced by an
immunization process with different intracellular antigens.
In rats, hemodynamic deterioration and myocarditis have
been reported after 3 weeks of immunization with cardiac
a-myosin or a-myosin peptides [173, 305]. This was
associated with increased expression and activity of
inducible nitric oxide synthase (iNOS) and an inhibitor of
that enzyme effectively attenuated the histopathologic
changes, thus pointing to a relevant pathophysiologic role
of nitric oxide (NO) [103, 104]. In mice, immunization
with a monoclonal anti-dog SERCA2a antibody caused
myocarditis [93].
Immunization of mice with recombinant murine cardiac
troponin I (mcTnI) resulted in myocardial deposition and
elevated serum levels of anti-mcTnI autoantibodies,
accompanied by myocardial inflammation (both humoral
and cellular immune response), cardiac dilatation, con-
tractile failure and increased mortality rate [83].
Systemic hypertension-induced HF
Spontaneously hypertensive rats (SHR)
Systemic hypertension is another relevant factor in human
CHF. Spontaneous hypertension is a natural model of
pressure overload, in which systemic hypertension leads to
HF with aging. Hypertensive vascular lesions appear
within 6–7 weeks, being more severe in males than in
females. For the first 12 months, the hypertrophy is
compensated and contractility is preserved, but after
18–24 months, there is overt CHF characterized by fibro-
sis, LV dilation and reduced systolic function [13, 100,
226]. These structural and functional changes occur in
tandem with a marked raise in cytokine levels such as
TNF-a and interleukin-6 [223]. Transition to failure has
been suggested to depend on significant alterations in the
expression of genes encoding extracellular matrix proteins,
oxidative stress and increased apoptosis of myocytes [1, 13,
15, 157, 273]. The gradual onset of hypertension with
aging makes this model suitable for studying the transition
from hypertrophy to CHF and for reproducing hyperten-
sion-induced CHF in humans [194]. It has the advantage of
avoiding the complications associated with surgical or
pharmacologic interventions, while mimicking the changes
found in human essential hypertension [16, 19]. Nonethe-
less, the long period required for developing CHF poses a
great limitation, making it a time-consuming and conse-
quently an expensive model. Additionally, this model has
other two relevant drawbacks, namely the absence of an
appropriate control and the complexity of the genetic
mutations, which have affected not only blood pressure but
many other regulatory systems as well.
The SHR stroke prone (SHR-SP) is a further developed
substrain with even higher levels of blood pressure and a
strong tendency to die from stroke [319].
Spontaneously hypertensive HF-prone rats (SHHF)
Spontaneous hypertensive rats carry the facp corpulent
gene, which encodes a defective leptin gene, and therefore,
they develop obesity and HF [41, 188]. The time for the
development of HF depends on facp gene dosage and
gender (male animals are more prone to HF than females
[96]) but, in general, SHHF rats present HF earlier than the
SHR strain, with loss of cardiac function starting at the age
of 15 months [100]. These animals present alterations in
the renin-angiotensin-aldosterone system (RAAS) and also
in calcium metabolism [82, 107, 188, 222]. The greatest
advantage of this strain is the possibility of studying drug
interventions in an extended range of cardiovascular risk
factors like obesity, diabetes and renal dysfunction [259].
Dahl-salt-sensitive rats
This is a mutant strain of Sprague–Dawley rats that are
characterized by hypersensitivity to sodium intake [48].
When placed on a high-salt diet from the 6th week of age,
they develop concentric LV hypertrophy without chamber
dilation around the 11th week and decompensate HF with
marked ventricular dilation between the 15th and the 20th
week [119, 139]. Failure is associated with reduced myo-
cardial performance as evidenced by the lower perfor-
mance of muscle strip preparations and the short lifetime of
failing rats [119]. Diastolic dysfunction, as well as
increased LV endothelin-1 production, collagen accumu-
lation and even survival could be improved more effec-
tively by a combination of angiotensin receptor blockers
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and angiotensin-converting-enzyme (ACE) inhibitors than
either agent alone [137].
Interestingly, it has been shown that introducing high-
salt diet at 7 or 8 weeks of age can result in distinct HF
phenotypes. Indeed, the 7-week starting rats showed a steep
elevation in blood pressure and progressive LV hypertro-
phy, falling into overt DHF at approximately 19 weeks. On
the other hand, the 8-week starting rats showed a gradual
rise in blood pressure and less progressive LV hypertrophy,
developing SHF at approximately 26 weeks. Therefore,
these two different models of overt HF may be useful as
models of isolated DHF and SHF based on the same
hypertensive heart disease, which could be relevant to the
pathophysiologic and molecular characterization of each
HF subtype [55]. Another report found that the develop-
ment of HF was dissociated from changes in passive dia-
stolic and active systolic properties, suggesting that volume
overload plays an important pathophysiologic role in the
development of HF despite preserved overall ventricular
pump function in this model of chronic hypertension [139].
This model is suitable to study the transition from
compensated hypertrophy to failure. Moreover, it is often
used to identify the role of several pathways and molecular
mechanisms like oxidative stress, extracellular matrix
degradation [289], calcium handling impairment [253] as
well as redox-regulated transcription factors [116] and
apoptotic factors activation [320].
DOCA-salt rats
The deoxycorticosterone acetate (DOCA) salt-induced
model of hypertension is a typical representative of phar-
macologically induced hypertension. A very high subcu-
taneous dose of DOCA is required to induce hypertension
in rats [268]. Isotonic saline is the sole drinking fluid,
which hastens and aggravates progression to hypertension
[280]. Despite being salt-dependent in its initiation, this
model frequently needs surgical reduction of renal mass or
unilateral nephrectomy. DOCA-salt hypertension is a low
renin and volume-overloaded form of hypertension. The
combination of DOCA-salt and unilateral nephrectomy
results in hypertension, renal hypertrophy, nephrosclerosis,
cardiac hypertrophy and myocardial and perivascular
fibrosis within 4–5 weeks of chronic treatment [89, 215].
The pathophysiologic mechanisms underlying the
development and maintenance of DOCA-salt hypertension
include increased levels of arginine vasopressin [120],
angiotensin-II/aldosterone [300, 313], endothelin [179,
204, 258, 302] and oxidative stress [154, 175], excessive
activation of the sympathetic nervous system [132] and
nitric oxide synthase (NOS) uncoupling due to oxidative
depletion of its cofactor tetrahydrobiopterin (BH4) [274].
Indeed, both inhibition of the angiotensin-aldosterone
system and endothelin receptor blockade have been shown
to prevent cardiac remodeling, even without concomitantly
reducing arterial blood pressure [89, 257]. Of notice, PPAR-
a activation has also a beneficial effect on myocardial
fibrosis and prevented diastolic dysfunction in DOCA-salt
rats by modulation of NF-jB inflammatory pathway [215].
Nonetheless, the cardiac consequences are minimal during
the development of DOCA-salt hypertension-induced
hypertrophy [29]. This is in contrast to the decreased
responses reported in other rat models of cardiac hypertro-
phy and in the failing human heart. Therefore, hypertrophy
in hearts of DOCA-salt hypertensive rats does not produce
similar changes to the failing human heart [29].
Of notice, a group recently published a mouse model that
combines a surgical intervention to induce pressure over-
load, namely transverse aortic constriction (TAC), with
DOCA administration, in the setting of normal-salt diet.
Compared with TAC mice, TAC plus DOCA mice had
similarly normal LV systolic pressure and fractional short-
ening but more hypertrophy, fibrosis and diastolic dysfunc-
tion with increased lung weights, consistent with HF with
preserved ejection fraction. There was progressive activa-
tion of markers of oxidative stress but no evidence of classic
mineralocorticoid receptor–dependent gene transcription.
Therefore, they suggest that pressure-overload hypertrophy
sensitizes the heart to mineralocorticoid excess, promoting
the transition to DHF without activation of the classic min-
eralocorticoid receptor-dependent gene transcription.
The major limitations of the DOCA-salt model are (1)
the need to employ a large amount of drug, (2) the
requirement for surgical reduction of renal mass and (3) the
dependence on a strictly controlled ingestion of a high
NaCl dose. On the other hand, its chief advantage is the
potential to investigate the role of sodium in the develop-
mental stages of hypertension.
2K1C rat
Since 1934, when Goldblatt and his co-workers induced an
elevation of blood pressure by partial constriction of the
renal artery of the dog [81], many successful models of
renal-induced experimental hypertension have been
developed in rats. In general, the procedure includes two-
kidney Goldblatt hypertension (constriction of one renal
artery while the contralateral kidney is left intact) and one-
kidney Goldblatt hypertension (one renal artery is con-
stricted and the contralateral kidney is removed) [280].
Clipping one renal artery, while leaving the contralateral
kidney untouched, induces systemic hypertension and LV
concentric remodeling within 8 weeks [131]. Histologic
studies revealed extensive LV fibrosis, while echocardi-
ography and hemodynamic data consistently shown dia-
stolic dysfunction [131]. Indeed, inhibition of matrix
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metalloproteinase activity in these hypertrophic hearts has
been shown to provide beneficial effects in terms of
structure and function [237]. At cellular level, several
changes in the energy metabolism, actin–myosin cross-
bridge cycle and protein expression were identified in
renovascular hypertensive rats [131]. In addition, the par-
amount role of activation of the RAAS [73, 150] and the
sympathetic nervous system [32, 270] has been thoroughly
studied. In the one-kidney model, no compensatory
increase in sodium and water excretion can occur, and
hence, fluid volume is retained, which means this model is
thus a sodium-fluid volume-dependent model. Therefore, it
would advantageous for studying the role of volume
expansion in the development of hypertension [11]. During
the early developmental stage, when the clip is removed,
arterial blood pressure returns to normal in both models,
suggesting that renovascular hypertension is both revers-
ible and reproducible [147].
Pressure-overload-induced HF
Aortic constriction (banding) is a well-established surgical
technique for induction of LV chronic pressure overload
and hypertrophy in rodents. The banding initially imposes
little or no restriction to aortic flow but gradually, as the
animal grows, the relative severity of the constriction
increases, resulting in cardiac hypertrophy. Aortic banding
in several positions has been used to mechanically repro-
duce the cardiac consequences of aortic stenosis, systemic
hypertension and coarctation of the aorta [111, 138, 203,
240, 279]. The constriction can be thoracic, either close to
the origin of the aorta, ascending aortic constriction
(AAC), or in the aortic arch between the first and second
trunks and named transverse aortic constriction (TAC).
Alternatively, the constriction can be performed in
abdominal aorta, either below or above the renal arteries,
the latter inducing hypertension by renal hypoperfusion
and concomitantly LV hypertrophy [34]. The anatomic
location of the constriction is the main responsible for the
differences between these models. In this context, AAC is
generally used to study the effects of early insult due to
pressure overload, while TAC and suprarenal aortic con-
striction display a more gradual rise of pressure, progres-
sion toward hypertrophy and HF [16].
The timeline of disease progression depends on the
selected species, age or gender, with mice subjected to
TAC presenting LV hypertrophy as early as 7 days [294]
and decompensate HF at 4 weeks [153], while rats present
slower progression [16], as illustrated in Fig. 1. For
instance, in weanling rats [70, 263, 309, 316], a TAC
surgery that reduces 50% of the aorta diameter creates a
systolic pressure gradient of *50–60 mmHg between the
aorta and the LV, inducing clear echocardiographic evi-
dence of LV hypertrophy, and increases left atrial pressure
around the 8th week [162]. After 18–20 weeks of com-
pensated LV hypertrophy, a subgroup of animals eventu-
ally decreases LV systolic pressure, accompanied by
increased LV volume, reduced ejection fraction and clini-
cal signs of overt CHF [309]. Moreover, molecular changes
have been reported with increased expression of b-myosin
heavy chain, atrial natriuretic peptide (ANP), interleukin-1,
interleukin-6 and TNF-a [200]. On the other hand, the
failing myocardium exhibits a reduced expression of
SERCA2a when compared to non-failing hypertrophied
heart, which suggested that decreased levels of SERCA2a
could be a marker of transition from compensatory
hypertrophy to failure in these animals [70].
Abdominal aortic banding in rats causes an initial
increase in contractility due to the compensatory activation
of the sympathetic nervous system [25] but after 8 weeks,
systolic and diastolic dysfunction as well as concentric
hypertrophy are evident [34, 67]. In mice, suprarenal
abdominal aortic banding causes cardiac hypertrophy
within 4 weeks as a compensatory response, which even-
tually leads to CHF after 15–21 weeks depending on the
degree of constriction as well as animal age, gender and
weight [94, 312]. Changes in NO pathway are believed to
play an important role in the pressure-overloaded heart and
pathologic cardiac remodeling. In fact, reports showed that
phosphodiesterase-5 (PDE5) inhibitor sildenafil reduces
LV hypertrophy and dilation in the mouse TAC model
[223, 290]. However, the most promising therapeutic
approach is represented by a new neutral sugar organic
nitrate, LA-419, the thiol group of which seems to protect
NO from degradation, thereby increasing its bioavailabil-
ity. In the aortic stenosis model, LA-419 has been found to
restore the complete NO signaling cascade and reduce LV
remodeling, but without restoring the original pressure
Fig. 1 Timeline progression of
transverse aortic constriction:
comparison between mice and
rat
224 Heart Fail Rev (2013) 18:219–249
123
gradient, indicating a possible direct antiproliferative effect
[243]. Additionally, the exogenous administration of the
NOS cofactor BH4 has been shown to reduce LV hyper-
trophy, fibrosis and cardiac dysfunction in mice with
pre-established pressure overload. In this setting, BH4
recoupled endothelial NOS, with subsequent reduction of
NOS-dependent oxidative stress and reversal of maladap-
tive remodeling [195, 196].
Among the major advantages that these banding models
share compared to other hypertensive or HF models is the
ability to manipulate the degree of pressure overload by
changing the constriction severity [197]. Concerning the
thoracic aorta constrictions, the main advantage is the
similarities to human HF progression, especially to aortic
stenosis patients. Accordingly, it is characterized by initial
compensatory phase, with concentric LV hypertrophy fol-
lowed by an enlargement of cardiac chambers associated
with a further deterioration of LV function [16]. Another
advantage is the extensive information regarding TAC
model: it was first described in 1994 by Rockman [240],
and it has been extensively used since then, especially in
mice either by traditional thoracotomy approach [67, 239]
or by minimally invasive aortic banding through a small
incision in the proximal sternum [111]. Finally, this
method permits the quantification of the pressure gradient
across the aortic constriction and the stratification of LV
hypertrophy [223]. However, the rat TAC model has sev-
eral drawbacks such as prolong duration of the protocols
(Fig. 1), inter-individual variability in the response to
pressure overload [198] and high proportion of debanding
due to internalization of the constriction knot [171]. These
two last disadvantages require the use of large experi-
mental groups and the use of accessory methods for visu-
alization of the constriction integrity and progression of
disease, such as echocardiography. Both AAC and TAC
models have a common disadvantage resultant from the
complex surgical method and equipment necessary for
open-chest microsurgery. The lack of such an extended
learning curve is the major advantage of abdominal con-
striction model, alongside with the low mortality rate
associated with banding (10%) [70]. Activation of RAAS
might however limit the use of abdominal aorta constric-
tion in some studies [241]. Moreover, decrease of LV
relaxation rates makes such models valuable for the eval-
uation of diastolic dysfunction, which is an important
factor in the progression of LV failure [69]. In addition, the
stimulus for HF is gradual in onset as is the progression
from compensated hypertrophy to HF in humans, thus
making it clinically more relevant. Recently, a minimally
invasive murine model of TAC debanding was described,
in which it is possible to remove the band up to 4 weeks
later through the same suprasternal incision [278]. This
reversible model of pressure overload turned out to be an
interesting model to study the molecular mechanisms
involved in LV reverse remodeling.
Volume-overload-induced HF
Arteriovenous shunts have been used to induce volume
overload and consequently dilated cardiomyopathy and HF
in rodents. Femoral artery to femoral vein fistulas lead to
HF, but present a reported mortality above 25% in all
studies [217]. The more recent aortocaval shunt is a rela-
tively simpler and faster alternative to induce HF with good
survival rates and no need to perform thoracotomy [28, 77,
231]. In rats, significant cardiac hypertrophy develops
4 weeks after shunt induction, with compromised LV
contractility and increased end-diastolic pressure [256].
Severe volume overload from a large aortocaval fistula
initially leads to depressed LV function followed by a
compensatory hypertrophy and near normal function at
4 weeks [165, 307]. Decompensated hypertrophy or CHF
develops between 8 and 16 weeks after the intervention
and is characterized by a decline in systolic and diastolic
function [34, 308] and a shift between myosin heavy chain
isoforms expression [307]. Nonetheless, shunt closure has
been reported in 7% of the cases, which means that it is
necessary to confirm the patency of the shunt at the end of
investigation. Of note that, not only the duration, but also
the size of the shunt will determine the onset and severity
of CHF in rats, with elevation of LV end-diastolic pressure
reported only in the overt CHF group caused by a large
shunt for a minimum period of 4 weeks [148]. This pro-
cedure has the advantage of being fast and usually well
tolerated, despite the limitation of requiring a laparotomy.
Another procedure used to induce volume overload in
rats is aortic valve regurgitation, in which an aortic valve
cusp is punctured [56, 207].
The neurohumoral activation of volume-overload mod-
els includes local activation of RAAS, which is associated
with depressed myocardial function [211]. Recent reports
found that ANP expression is a more sensitive marker of
volume overload than pressure overload [36]. In addition,
long-term overexpression of SERCA2a in this animal
model can preserve systolic function and potentially pre-
vent diastolic dysfunction and LV remodeling [134].
Diabetic cardiomyopathy-induced HF
Animal models have been extensively used in diabetes
research. Their utility can be questioned due to species
differences; however, rodent models share many features
with human diabetic cardiomyopathy. For example, rodent
models of obesity, insulin resistance and type 2 diabetes
present LV hypertrophy, diastolic dysfunction, increased
cardiac fatty acid uptake and utilization, decreased cardiac
Heart Fail Rev (2013) 18:219–249 225
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efficiency, impaired mitochondrial energetics, increased
myocardial lipid storage, and impaired Ca2? handling [4,
19, 31].
There are a number of pharmacologic rodent models of
diabetes: streptozotocin (STZ) administration to rats or
mice, which induces diabetes mellitus (DM) as soon as
48 h post-injection [295]. This substance is selectively
toxic to b-cells in the pancreatic islets, induces insulin
deficiency and hyperglycemia and therefore represents a
model of type 1 diabetes.
On the other hand, selective inbreeding has produced
several strains of animal that are considered reasonable
models of type 1 diabetes, type 2 diabetes and related
phenotypes such as obesity and insulin resistance
(Table 1). Apart from their use in studying the pathogen-
esis of the disease and its complications, all new treatments
for diabetes, including islet cell transplantation and pre-
ventive strategies, are initially investigated in animals. In
recent years, a large number of new genetic animal models
for the study of diabetes, including knock-in, generalized
and tissue-specific knockout mice, have been described.
Rodent models of type 2 diabetes include the Zucker fatty
rat, as well as db/db and ob/ob mice, all of which display
dysfunctional or absent leptin homeostasis and therefore
develop insulin resistance in different timepoints.
In vivo studies in these rodents have revealed suscepti-
bility to systolic and diastolic dysfunction using echocar-
diography and hemodynamic measurements [301]. They
also exhibit a propensity to ischemia/reperfusion injury
following LAD ligation, which occurs in conjunction with
structural and functional changes to the LV [87]. However,
there are several limitations when comparing these models
to human diabetic cardiomyopathy, as spontaneous ische-
mia and atherosclerotic disease are not prominent in
rodents [18]. The latter becomes simultaneously a valuable
aspect as the effects of obesity, insulin resistance and
diabetes on the heart can be studied independently of
coronary artery disease [121]. Importantly, rodent models
present fulminant and uncontrolled hyperglycemia or
insulin resistance, while in the clinical setting patients with
diabetes are increasingly well controlled as demonstrated
by a recent study which found no evidence for diabetic
cardiomyopathy in well-controlled patients with type 1
diabetes [141]. Moreover, because DM develops at varying
stages in these models, it is important to keep in mind that
studies performed in animals before the onset of diabetes
may reflect changes that are secondary to the underlying
obesity and insulin resistance, and studies performed after
the onset of diabetes may reflect the added effects of
hyperglycemia of different durations.
In conclusion, each model has certain limitations and no
perfect model exists that exactly mimics human diabetic
cardiomyopathy (Table 1).
Diastolic HF models
In spite of the rising prevalence of DHF, currently there is
no evidence-based treatment strategies capable of changing
its natural history, reflecting our poor understanding of this
HF subtype [314]. Therefore, animal models of diastolic
dysfunction and DHF urge for the development and pre-
clinical evaluation of new effective therapies for this dis-
ease. However, animal models of DHF are rather scarce,
thus leading to the utilization of diastolic dysfunction
models, which are more widely published and very similar
regarding the basic pathophysiologic mechanisms [60].
Furthermore, these models have been most commonly
created in large animals, such as canine, sheep and swine.
Nonetheless, there have been some successful rodent
models that deserve to be highlighted in this review.
Animal models have tried to reproduce the paramount
risk factors typically associated with diastolic dysfunction
and DHF, namely aging, diabetes mellitus and hyperten-
sion [327]. In fact, the alterations in myocardial relaxation
and stiffness associated with chronic hypertension
and diabetes have been already mentioned above in the
appropriate models, namely Dahl-salt-sensitive rats,
DOCA-salt rats and diabetic cardiomyopathy.
Despite the great difficulty in developing an animal
model of DHF age-induced, a recent study has character-
ized a model demonstrating isolated diastolic dysfunction
associated with accelerated aging [235]. This mouse model
is a spontaneous senescence model that displays many
common geriatric disorders in the human population and
recapitulates diastolic dysfunction as it naturally occurs in
the elderly. Diastolic dysfunction, accompanied by fibrosis
and an increase in pro-fibrotic cytokines, develops between
3 and 6 months of age, which is an early timepoint in the
life span of these animals. This suggests that the physio-
logic abnormality manifests over a relatively short period
of time and, from an experimental standpoint, adds
an advantage as it allows for a more rapid study of
pathophysiologic mechanisms. The senescence-accelerated
mouse model will probably turn to be a useful model for
future studies of age-related diastolic dysfunction, since the
better insight into its underlying mechanisms could pave
the way for designing specific pharmacologic strategies to
prevent or treat this pathology [235].
The association between aging and diastolic dysfunction
had already been addressed in a previous study, which
compared adult (6-month-old) and old (24-month-old)
Fischer 344/BNF1 rats after either 12 weeks of treadmill
training or normal sedentary cage life [26]. Echocardio-
graphic indices of LV relaxation were significantly lower
in the old rats, but with training, they increased back to the
levels seen in the adults. LV stiffness measured in isolated
perfused hearts was not affected by age or training, but
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increased more rapidly during low-flow ischemia in the old
hearts than in the adults. Again, training eliminated this
age-associated difference in the response to ischemia,
although it was not ascertained if the improvement was due
to reversal of aging consequences or superimposition of
some other effects. These findings indicate that in rats
some age-associated changes in diastolic function are
reversible and thus may not be intrinsic to aging but instead
secondary to other processes, such as deconditioning [26].
Syrian cardiomyopathic hamster
The Syrian cardiomyopathic hamster is an established
animal model for genetic cardiomyopathy, which has been
extensively used since it was firstly described in 1962 by
Homburger et al. [109]. They characterized an inbred line
of Syrian hamster named BIO1.50 that experienced both
cardiomyopathy and muscular dystrophy with 100% pen-
etrance and [109] present an autosomal recessive mode of
transmittance [109], thus being very useful for studying
both cardiac and skeletal muscle disorders. Afterward,
selective crossings gave rise to a new line, BIO14.6, which
is now more widely used throughout the world [110].
Indeed, hitherto several cardiomyopathic hamsters (CM
hamsters) have been derived from BIO14.6. Jasmin and
colleagues established a new inbred line of UMX7.1 by
cross-breeding BIO14.6 with unrelated healthy hamsters
[126]. Later, another substrain of these hamster was iso-
lated, the J2N [210]. The descendants of BIO14.6 and
UMX7.1 were named as CHF146 and CHF147, respec-
tively, and have been maintained at Canadian Hybrid
Farms in Nova Scotia, Canada [113]. All the five CM
hamsters (BIO14.6, UMX7.1, J2N, CHF146 and CHF147)
develop an identical cardiomyopathy, progressing through
prenecrotic, necrotic, hypertrophic and dilated stages [108].
Therefore, the disease progression in the hamster parallels
the human genetic disease [66].
The most remarkable genetic manipulation of CM
hamsters is the isolation of BIO53.58 from BIO14.6 [108].
Contrary to their forebears, BIO53.58 has a shorter life-
expectancy and achieves much faster the disease endpoint
of marked chamber dilation, which is common to all the
CM hamsters, apparently without developing previous
cardiac hypertrophy. Several descendants of BIO53.58,
such as TO, TO-2 and MS200, were developed [180], and
TO-2 is now maintained at Bio-Research Institute.
All the CM hamsters share the genomic deletion of
about 30-kb interval, which includes the two promoters and
first exons of delta-sarcoglycan gene with consequent loss
of its protein product [212, 248, 249]. The consequences of
the genetic loss of delta-sarcoglycan in heart are related
not only to sarcolemmal fragility but also to coronary
vasospasm from disruption of dystrophin-associated pro-
tein complex [44]. A genetic insult yet to be discovered
was probably introduced during the isolation of BIO53.58
and has been inherited by its descendants, which could
explain its distinct cardiomyopathy.
Pathophysiologically, two basic mechanisms contribute
to cardiomyopathy in this model: (1) ischemic heart disease
by vasospasm of the coronary circulation and (2) cardio-
myocyte loss due to intrinsic cell defects [66]. Reports
suggested that the vascular RAAS plays a critical role in
the generation of increased coronary reactivity and resis-
tance in young Syrian CM hamsters that have not yet
developed the clinical manifestations of HF, being the
increased reactivity due to endothelial dysfunction sec-
ondary to angiotensin-II-dependent oxidative stress [66].
Indeed, blockade of the RAAS during early stages of dis-
ease improves the clinical manifestations of dilated car-
diomyopathy in this model [66]. With regard to
cardiomyocyte loss, numerous studies showed autophagic
vacuolar degeneration in cardiomyocytes, which could be
improved by treatment with granulocyte colony-stimulat-
ing factor [288]. Another report provided novel evidence of
a beneficial effect of vascular endothelial growth factor in
the Syrian CM hamster via induction of myogenic growth
factor production by skeletal muscle and mobilization of
progenitor cells, which resulted in attenuation of cardio-
myopathy and repair of the heart [328].
Moreover, the Syrian CM hamster has been shown to
develop alterations in electrical and ionic homeostasis
related to disruption of gap junctions, which contributes to
arrhythmogenesis during the development of HF [247]. A
recent report showed that adhesion junction precedes
gap junction alterations and that angiotensin-II receptor
blockade might be a new therapy for lethal ventricular
arrhythmia by modulating both adhesion junctions and gap
junctions remodeling [323].
In summary, several reports confirm that CM hamsters
with genetic loss of delta-sarcoglycan recapitulate many
pathophysiologic aspects of cardiac failure [39, 267, 296],
but it is clear that despite its extended use, this model is far
from being totally understood [247].
Genetically engineered rodent models
The development of molecular biology offers the oppor-
tunity to study the impact of overexpression or deletion of
specific genes involved in the pathophysiology of CHF.
Indeed, transgenic murine models will help understanding
the molecular basis of CHF, which might open the door for
the development of novel molecular targets for the treat-
ment of CHF. A wide number of genetic modifications
have been successfully introduced in mice, either in terms
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of gain or loss of function. Besides the genetically engi-
neered mouse models summarized in Table 2, other
selective inbreed and other genetic animal models were
presented in previous sections whenever appropriate.
General considerations
Besides ethical and philosophical questions, the use of
animal models of HF needs careful consideration not only
because the disease may be associated with discomfort and
pain to the animal but also because results from animal
studies are not readily transferable to human patients.
HF models were originally developed in rodents because
of numerous potential advantages inherent to a small ani-
mal model. Housing and maintenance costs for rodents are
much lower than for larger animals, thus allowing
increasing the number of animals included in a given study
and improving its statistical power. Moreover, recent
technological advances in echocardiography, MRI and
micromanometer conductance catheters have greatly
upgraded the assessment of cardiac function in rodents,
removing a significant barrier to their use in HF research.
The small size of mice presents some challenges in
assessing myocardial function by conventional techniques
(echocardiography, MRI), and the tenfold bigger myocar-
dial mass of rats compared to mice gives the opportunity of
performing more post-mortem histologic and biological
analyses [223]. Nevertheless, cardiac physiologic assess-
ments have been made easier by recent technologies such as
ultrahigh resolution ultrasound [169] and micromanometer
conductance for pressure–volume analyses [80, 218], but
these techniques are quite expensive and pose a serious
challenge to laboratories without an established expertise.
The major advantage of mice compared to rats is the fact
that pharmacologic studies become less expensive as the
drug is usually administered proportionately to the animal
weight. Moreover, mice are one of the most interesting
research models to study the molecular basis of HF due to
the availability of many genetically engineered strains made
possible by their well-characterized genome and the easy
introduction and stable transmission of gene mutations.
Moreover, since 99% of the human genes have direct
orthologs with mice, it is possible to generate transgenic
mice models to mimic human disorders [71, 244]. Never-
theless, structural differences regarding human cardiovas-
cular system represent another limitation of rodent models.
With regard to diastolic dysfunction, it should be
emphasized that rodent models generally progress to SHF
within a variable amount of time, which means in those
animals DHF is only temporary step in the development of
SHF. On the contrary, there are several human pathologies
characterized by stable and isolated DHF, thus not evolving
to systolic dysfunction. Therefore, small animal models
could be misleading because they suggest that DHF
invariably progress to SHF, which in fact seldom happens
in humans. Additionally, in humans, DHF is a condition
typically associated with aging, and the diastolic dysfunc-
tion/DHF animal models herein mentioned are relatively
young.
Care should be taken when dealing with genetically
engineered mice. Besides taking into account strain and
gender issues [91, 272, 283], high levels of overexpression
must be carefully interpreted. In fact, transgenic mice that
express a biologically inert green fluorescent protein in a
cardiomyocyte-specific fashion develop LV hypertrophy,
dilation and systolic dysfunction in a manner directly
related to the level of protein expression. Therefore, non-
specific effects on LV structure and function may result
from vast overexpression of even biologically inactive
proteins [112]. Furthermore, certain phenotypes depend on
the expression level of the gene concerned [43, 298], which
means it is necessary to develop multiple transgenic lines
to establish a gene-dosage effect. Development of com-
pensatory mechanisms could be triggered in response to
gene overexpression or deletion at a very early stage after
manipulation, masking the direct effects of the targeted
gene. The use of inducible and conditional gene activation
or deactivation could be a good way of overcoming this
problem [306]. In conclusion, despite the inherent pitfalls
in transgenesis, many of them can be circumvented by
creating additional transgenic lines that can be used as
controls to check dosage or epigenetic sequelae, as has
been recently reviewed [202]. A number of difficulties in
interpreting a cardiac transgenic experiment can arise from
the promoter that drives the transgene itself. For example,
although the a-myosin heavy chain (a-MHC) promoter is
often thought of as driving ventricular expression in the
adult, its actual expression pattern is considerably more
nuanced, with transient expression in the embryonic heart
tube and atrial expression throughout development. If the
experimenter is attempting to isolate events that occur as a
result of expression only in the adult, more precise
manipulation of transgene expression may be necessary to
generate interpretable data. Inducible transgene expression
allows precise and reversible expression of a normal or
mutated protein that can be directed to a particular cell type
at a particular developmental time. A number of drug-
inducible systems have been described, but the tetracy-
cline-based system is the most effective and widely used.
However, like most tools, it must be used carefully as the
tetracycline activator can, when expressed at high levels or
for long periods of time, be cardiotoxic. Despite this con-
cern, transactivator lines have been developed that show no
cardiotoxicity for at least 6 months, and so these experi-
mental limitations can be easily circumvented [250].
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Gene targeting has often been heralded as being more
precise and useful than transgenesis. When coupled with
tissue- or cell type–specific methodologies via Cre-lox
technology, gene targeting offers a precise way of intro-
ducing specific mutations that will only be expressed in a
defined cell type at a particular developmental time.
Nonetheless, the continuous expression of the Cre recom-
binase system has been shown to cause decreased growth,
cytopathic effects and chromosomal aberrations in cultured
cells lacking exogenous lox sites [260, 275]. A self-
excising retroviral vector that incorporates a negative
feedback loop to limit the duration and intensity of Cre
expression can avoid measurable toxicity, while retaining
the ability to excise a target sequence flanked by lox sites,
thus providing the basis of a less toxic strategy for the use
of Cre or similar recombinases [275]. As is the case for
transgenesis, the more precisely the targeting event can be
manipulated, the more straightforward the data interpreta-
tion will be. In the heart, this is accomplished by rendering
the targeting event cardiomyocyte specific via controlled
Cre expression using a cardiomyocyte-specific promoter or
even making cardiomyocyte-specific Cre expression
inducible [277]. However, several reports have noted some
cardiac toxicity due to high levels of Cre expression with
the a-MHC promoter, especially in later adulthood [202].
One putative solution is to design the experiment such that
the data are obtained before cardiac function and bio-
chemistry are affected, circumventing any negative effect
of Cre expression. More importantly, employing Cre-only
transgenic mice in the same genetic background as part of
the overall experimental design is absolutely necessary for
proper data interpretation and to ascertain any potential
effect of Cre alone. Alternatively, different cardiac Cre
transgenes may be used. Moreover, tamoxifen administra-
tion only in the presence of the a-MHC-MerCreMer
transgene produces a temporary reduction in cardiac
function with some ventricular dilation, although this
phenotype resolves in 7–14 days after tamoxifen adminis-
tration [202]. Thus, if the MerCreMer transgene is used to
inducibly delete a gene from the heart, controls that only
contain this transgene with tamoxifen are critical.
Another drawback of rodent models is that many pro-
tocols have a sudden onset of HF due to a surgical or drug
intervention, whereas human HF generally develops over a
period of several years. Most models also use young adult
animals, while human patients are usually old. In addition,
human HF is often associated with atherosclerosis, hyper-
tension, diabetes or obesity, but the development of ath-
erosclerosis is rather rare in most rodent strains [92].
In addition, even though rodent models have been
extremely useful in developing concepts concerning the
pathogenesis of heart failure, apart from the Pfeffer’s
model [228], which predicted the utility of ACE inhibitorsT
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in post-infarction [227], they have not predicted outcomes
in phase III clinical trials. Although translation of findings
to clinical trials requires preclinical studies where the
appropriate animal model is used for either acute or chronic
HF, therapeutic results obtained in small animal models are
not necessarily predictive of outcomes in human patients
but can provide a potential future approach in the human
context. In this regard, two recent examples could be
mentioned. Inhibitors of enzymes in the PDE5 family have
been used to raise cGMP content in cardiac muscle in
animal models of pressure overload, chronic b-adrenergic
receptor stimulation, ischemic injury and doxorubicin
toxicity showing antihypertrophic and cardioprotective
actions. However, recent experimental results raise some
question regarding the applicability of these findings to
humans, in whose hearts PDE5 is present at much lower
levels than those seen in animal models, and raise the
possibility of PDE1, a dual-specificity phosphodiesterase
present at high levels in human myocardium, as an alter-
native target for inotropic and cardioprotective actions
[205]. On the other hand, despite the evidence for inflam-
matory activation as an important pathway in disease
progression in chronic HF and the promising results of
‘anti-inflammatory’ therapies (such as antitumor necrosis
factor-a approaches) in rodent models [146], clinical trials
have hitherto failed to show benefit in HF patients [101].
The discrepancy between clinical and basic research find-
ings could be explained by the inherent physiologic dif-
ferences between humans and rodents in terms of
pharmacokinetics and pharmacogenetics. On the other
hand, several authors reinforce the importance of refining
patient selection in order to optimize the benefits of new
HF drugs [101, 174].
Finally, the majority of the numerous genetic studies
performed in mice have not resulted in clinically approved
treatment in humans thus far [202]. However, it is not
uncommon for a drug to take over 20 years from inception
to clinical application. Given that genetically modified
mouse models have only recently become a mainstay
approach, it may take many more years before approaches
based on this technology are introduced into clinical
practice.
Conclusion
The use of small animal models has proven to be an
extremely valuable tool in understanding the pathophysi-
ology of complex cardiovascular diseases like CHF. Due to
the recent development of invasive and non-invasive
techniques to evaluate hemodynamics in human patients,
animal models of HF are becoming less important to study
hemodynamics, neurohumoral activation and myocardial
function. Furthermore, with cardiac transplantation sur-
gery, end-stage human myocardium become available for
molecular and biochemical studies. Nevertheless, animal
models remain critically important to study myocardial
changes during compensated, initial stages of CHF, during
transition from hypertrophy to failure and during the pro-
cess of remodeling, all of which are currently difficult or
even impossible to follow serially in human patients.
Animal models may also be relevant to study the effects
of new pharmacologic interventions on hemodynamics,
neurohumoral activation and survival under preclinical
conditions.
At present, transgenic models of CHF are essential for
understanding the molecular alterations underlying the
development of the disease, as they allow the identification
of genes that are causative for HF and to characterize
molecular mechanisms responsible for the development
and progression of the disease.
Finally, animal models that mimic distinct features of
human HF will play an important role in unraveling the
consequences of gene transfer and molecular techniques to
correct disturbed subcellular processes in the failing heart.
These experiments are indispensable, and these rodent
models will continue to held an important role, not only in
expanding our knowledge about the mechanisms underly-
ing HF, but also in developing novel therapeutic strategies
for CHF.
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